outcomes_strategies_drug_utilization
View more presentations from z15sefap.
Showing posts with label Z15. Show all posts
Showing posts with label Z15. Show all posts
Sunday, 14 November 2010
Influencing Prescribing in Primary Care in the NHS
Labels: Z15influencing prescribing primary care
View more presentations from z15sefap.
Medicines Information provision in the UK
Labels: Z15medicine_information in the uk
View more presentations from z15sefap.
Thursday, 26 August 2010
EVALUATION OF HEALTH OUTCOMES AFTER IMPLEMENTATION OF DIFFERENT STRATEGIES TO ACHIEVE RATIONAL USE OF DRUGS IN BRITISH COLUMBIA.
Labels: Z15
James Wright. Managing Director and Chair, Therapeutics Initiative. University of British Columbia. Vancouver (Canadá).
Background
The Therapeutics Initiative was established in 1994 with two main mandates: 1) to provide physicians and pharmacists with up-to-date, evidence-based, practical information on prescription drug therapy, and 2) to advise the Ministry of Health on the best available evidence of benefits and harms of new and existing prescription drugs. In the beginning we had the privilege of working with a small number of enlightened individuals within Pharmacare in the Ministry. Pharmacare and the Therapeutics Initiative had the common goal of optimizing use of prescription drugs and appreciated that prescribing practices in general were far from optimal.
Policies implemented
1. Therapeutics Letter 6 times per year to provide physicians and pharmacists with the best available evidence about the benefits and harms of drugs and drug classes.
2. Letters provide drug cost information for physicians.
3. Funding of new drugs was based on the best available evidence; a new drug only became a full benefit if it represented a therapeutic advantage or a cost advantage over appropriate alternatives (outcomes based coverage).
4. Reference based pricing of equivalent drugs within a drug class.
5. Restricted access with exemptions in special cases.
Reasons why the policies were successful
1. The Therapeutics Initiative did not allow anybody with a conflict of interest to participate in decision-making about assessment of evidence.
2. Setting up the questions for systematic review was an interactive process.
3. The drug assessment working group followed Cochrane methodology and improved their skills at critical appraisal and assessing risk of bias over time.
4. Independent researchers were contracted to evaluate the impact of the policies on drug utilization and health outcomes.
5. Ministry of Health personnel remained committed to outcomes based coverage despite political pressures.
Outcomes
1. The Therapeutics Initiative (TI) and Letter (TL) had a high acceptance rate based on a 2006 survey: >80% of general practitioners and >90% of pharmacists felt the TI was meeting its mandate. TL 64 Your opinions of the Therapeutics Letter. The 2006 Survey. http://www.ti.ubc.ca/letter64 full report. http://ti.ubc.ca/PDF/Survey2006Report.pdf
2. Drug utilization and drug costs are substantially lower in BC for most classes of drugs as compared to the rest of Canada. TL 72 Prescription drug costs. BC vs Canada. http://www.ti.ubc.ca/letter72
3. The different policies were shown to NOT have an adverse effect on health care utilization or health outcomes (eg. Outcomes of reference pricing of angiotensin-converting-enzyme inhibitors. N Engl J Med 2002;346:822-9)
4. Enormous pressure was put on the government to abolish the Therapeutics Initiative and drug policies.
5. No new drug classes (eg. Statins) have been subjected to the reference based pricing policy since 1998.
Conclusion
I will end my talk by a discussion of:
1. The lessons learned by the Therapeutics Initiative during the last 16 years.
2. What is wrong with the global system of prescription drug discovery, clinical drug trials, drug marketing, and drug regulation?
3. Ways in which the system could be improved.
Therapeutics Letter diciembre de 2008
The Canadian Rx Atlas
Therapeutics Letter mayo de 2007
OUTCOMES OF REFERENCE PRICING FOR ANGIOTENSIN-CONVERTING–
ENZYME INHIBITORS
Background
The Therapeutics Initiative was established in 1994 with two main mandates: 1) to provide physicians and pharmacists with up-to-date, evidence-based, practical information on prescription drug therapy, and 2) to advise the Ministry of Health on the best available evidence of benefits and harms of new and existing prescription drugs. In the beginning we had the privilege of working with a small number of enlightened individuals within Pharmacare in the Ministry. Pharmacare and the Therapeutics Initiative had the common goal of optimizing use of prescription drugs and appreciated that prescribing practices in general were far from optimal.
Policies implemented
1. Therapeutics Letter 6 times per year to provide physicians and pharmacists with the best available evidence about the benefits and harms of drugs and drug classes.
2. Letters provide drug cost information for physicians.
3. Funding of new drugs was based on the best available evidence; a new drug only became a full benefit if it represented a therapeutic advantage or a cost advantage over appropriate alternatives (outcomes based coverage).
4. Reference based pricing of equivalent drugs within a drug class.
5. Restricted access with exemptions in special cases.
Reasons why the policies were successful
1. The Therapeutics Initiative did not allow anybody with a conflict of interest to participate in decision-making about assessment of evidence.
2. Setting up the questions for systematic review was an interactive process.
3. The drug assessment working group followed Cochrane methodology and improved their skills at critical appraisal and assessing risk of bias over time.
4. Independent researchers were contracted to evaluate the impact of the policies on drug utilization and health outcomes.
5. Ministry of Health personnel remained committed to outcomes based coverage despite political pressures.
Outcomes
1. The Therapeutics Initiative (TI) and Letter (TL) had a high acceptance rate based on a 2006 survey: >80% of general practitioners and >90% of pharmacists felt the TI was meeting its mandate. TL 64 Your opinions of the Therapeutics Letter. The 2006 Survey. http://www.ti.ubc.ca/letter64 full report. http://ti.ubc.ca/PDF/Survey2006Report.pdf
2. Drug utilization and drug costs are substantially lower in BC for most classes of drugs as compared to the rest of Canada. TL 72 Prescription drug costs. BC vs Canada. http://www.ti.ubc.ca/letter72
3. The different policies were shown to NOT have an adverse effect on health care utilization or health outcomes (eg. Outcomes of reference pricing of angiotensin-converting-enzyme inhibitors. N Engl J Med 2002;346:822-9)
4. Enormous pressure was put on the government to abolish the Therapeutics Initiative and drug policies.
5. No new drug classes (eg. Statins) have been subjected to the reference based pricing policy since 1998.
Conclusion
I will end my talk by a discussion of:
1. The lessons learned by the Therapeutics Initiative during the last 16 years.
2. What is wrong with the global system of prescription drug discovery, clinical drug trials, drug marketing, and drug regulation?
3. Ways in which the system could be improved.
Therapeutics Letter diciembre de 2008The Canadian Rx AtlasTherapeutics Letter mayo de 2007OUTCOMES OF REFERENCE PRICING FOR ANGIOTENSIN-CONVERTING–ENZYME INHIBITORS
Thursday, 15 July 2010
SCIENTIFIC PROGRAMME
Labels: Z15
Download programme (PDF)WEDNESDAY 27TH OCTOBER 2010
16:00-19:00 Pre-Congress Workshops.
Workshop 1. Risk-sharing agreements: New strategies to drug reimbursement decisions.
Antoni Gilabert Perramon.
Josep Lluís Segú Tolsa.
Cristina Espinosa Tomé.
Workshop 2. Web 2.0 and internet resources: tools to manage scientific knowledge.
Ernesto Barrera Linares.
Cruz Bartolomé Moreno.
Workshop 3. Decision making: Other Evidence Based Products.
Juan Ignacio Martín Sánchez.
Workshop 4. From evidence to recommendations: the GRADE system.
Arritxu Etxeberria Agirre.
Rafael Rotaeche del Campo.
Workshop 5. Development of effectiveness indicators related to the clinical management.
Mª José Calvo Alcántara.
Olga Larrubia Muñoz.
Workshop 6. Conflict resolution strategies.
Jesús Ángel Sánchez Pérez.
20:30 Welcome reception at the Zaragoza City Hall. Cocktail.
THURSDAY 28TH OCTOBER 2010
9:00-10:30 Oral Communication session 1
Chairperson: Flora Pérez Hernández.
10:30-11:00 Opening Ceremony
11:00-11:30 Coffee Break. Poster viewing. Exhibition
11:30-13:00 Round Table 1: Challenges and opportunities of primary care pharmacy on new technologies.
Chairperson: Javier Garjón Parra.
Lecture 1: Health professionals adaptation to new technologies.
José Manuel Picas Vidal.
Lecture 2: Clinical decision support systems in clinical practice.
Eva Comín Bertrán.
Lecture 3: Clinical evaluation of prescription: One step forward.
Encarnación Cruz Martos.
Lecture 4: Pharmacotherapeutic follow-up: role of new technological tools.
Nora Izko Gartzia.
13:00-14:30 Opening Lecture: Management of illusion in changing times.
Emilio Duró Pamies.
14:30-16:00 Lunch.
16:00-17:30 Oral Communication session 2
Chairperson: Ana Mª Sangrador Rasero.
17:30–18:00 SEFAP Strategic plan presentation 2010-2013.
Arantxa Catalán Ramos. Presidenta de la SEFAP
18:00 E-Posters discussion (atended).
20:30 Guided tour: Historic center of Zaragoza and Pilar Basílic .
FRIDAY 29TH OCTOBER 2010
9:30-11:00 Oral Communication session 3
Chairperson: Luis Carlos Saiz Fernández.
11:00-11:30 Coffee Break. Poster viewing. Exhibition.
11:30-13:00 Round Table 2: National and internacional experiences: a vision to share.
Chairperson: Pilar Astier Peña.
Lecture 1: Influencing prescribing in primary care in the NHS.
Janice Steele.
Lecture 2: Medicines Information in the UK.
David Erskine.
Lecture 3: Pharmaco-epidemiological studies in partnership with BIFAP. First experiences.
Juan Erviti López.
Lecture 4: Variability on pharmaceutical prescription. Is geography destiny too?.
Enrique Bernal Delgado.
13:00-14:00 Closing Lecture: “Evaluation of health outcomes after implementation of different strategies to achieve rational use of drugs in British Columbia.
James Wright.
14:00-14:30 Closing Ceremony of XV Congress of SEFAP.
14:30-16:00 Lunch.
16:00-18:00 General Assemby of SEFAP.
21:00 Clossing Dinner. Prize giving: Oral communications and e-posters.
Available on www.sefap.org
Friday, 9 July 2010
Presentation
Labels: Z15
Dear colleagues,
From the 27th to the 29 th of October 2010, the Fifteenth Congress of the Spanish Society of Primary Care Pharmacists will be held in Zaragoza.
After 15 years of our society we want this congress to be an opportunity to celebrate and show our gratitude to everybody who has worked there for primary care pharmacy. Also, it gives us a chance to look at the present and future and reflect on what the current context provides to primary care pharmacist. Therefore, our motto we have chosen for this congress is: " Primary Care Pharmacy: Challenges and Opportunities ".
We will address issues such as the application of information and communication technologies and Web 2.0 in the improvement of drug use (prescribing support systems, reduction of medication errors, dissemination of information on medicines to professionals and patients, etc.), pharmaceutical care and health education, development of quality indicators, and explore national and international alliances with organisations involved with the rational use of drugs.
We want this congress to be a forum where all professionals can share, discuss and reflect on the challenges and opportunities of Primary Care Pharmacy, and to be a source of encouragement to build a bridge that turn difficulties into opportunities.
We are looking forward to hearing from you
Kind regards
Presentation Video
From the 27th to the 29 th of October 2010, the Fifteenth Congress of the Spanish Society of Primary Care Pharmacists will be held in Zaragoza.
After 15 years of our society we want this congress to be an opportunity to celebrate and show our gratitude to everybody who has worked there for primary care pharmacy. Also, it gives us a chance to look at the present and future and reflect on what the current context provides to primary care pharmacist. Therefore, our motto we have chosen for this congress is: " Primary Care Pharmacy: Challenges and Opportunities ".
We will address issues such as the application of information and communication technologies and Web 2.0 in the improvement of drug use (prescribing support systems, reduction of medication errors, dissemination of information on medicines to professionals and patients, etc.), pharmaceutical care and health education, development of quality indicators, and explore national and international alliances with organisations involved with the rational use of drugs.
We want this congress to be a forum where all professionals can share, discuss and reflect on the challenges and opportunities of Primary Care Pharmacy, and to be a source of encouragement to build a bridge that turn difficulties into opportunities.
We are looking forward to hearing from you
Kind regards
Mª José Buisán Giral
Chair of the Organising Committee
Chair of the Organising Committee
Mª Concepción Celaya Lecea
Chair of the Scientific Committee
Chair of the Scientific Committee
Presentation Video
What is SEFAP
Labels: Z15
What is SEFAP?
The Spanish Society of Primary Care Pharmacists is a scientific and professional association founded with the aim of promoting all activities aimed at ensuring optimal use of medicines in the field of primary care.
What are the goals of the SEFAP?
To organise as a collective all healthcare professionals associated with the drug in the field of primary care.
To respond to professional needs expressed by their members.
To promote the social recognition of primary care pharmacists.
To participate in the making of decisions about drug policy that Health Administration introduces.
To enhance the professional practice of primary care pharmacist in the National Health System.
To facilitate the exchange of experiences among members of the Society.
To develop specialised postgraduate education programs.
To provide education tools for the proper professional practice of the members.
To promote and coordinate research related to the use of drugs.
To establish relationships with other health professional societies framed in primary care.
What activities are performed by SEFAP?
Establishing the necessary communication systems to facilitate the dissemination of information about education and information activities among its members.
Hearing in the procedures for preparation of pharmaceutical management laws of the Autonomous Communities.
Building relationships with the media both professional and general.
Definition and dissemination of functions of the pharmacist integrated in primary health care structures.
Definition and dissemination of postgraduate specialisation program of the primary care pharmacist.
Elaboration of Informative Series: working papers with educational purposes.
Establishment of an annual educational offer specifically oriented to primary care pharmacist.
Promotion of grants intended to facilitate access to the annual educational offer.
Promotion of research through calls for awards.
Accreditation of promotional materials and training activities specifically directed at members of society.
Making the annual congress of the society.
Organization of expert groups for the analysis of pharmaceutical policy issues in the aspects clinical, economic and social.
Organization of seminars on current issues related to activities in different territories represented on the Board.
The Spanish Society of Primary Care Pharmacists is a scientific and professional association founded with the aim of promoting all activities aimed at ensuring optimal use of medicines in the field of primary care.
What are the goals of the SEFAP?
To organise as a collective all healthcare professionals associated with the drug in the field of primary care.
To respond to professional needs expressed by their members.
To promote the social recognition of primary care pharmacists.
To participate in the making of decisions about drug policy that Health Administration introduces.
To enhance the professional practice of primary care pharmacist in the National Health System.
To facilitate the exchange of experiences among members of the Society.
To develop specialised postgraduate education programs.
To provide education tools for the proper professional practice of the members.
To promote and coordinate research related to the use of drugs.
To establish relationships with other health professional societies framed in primary care.
What activities are performed by SEFAP?
Establishing the necessary communication systems to facilitate the dissemination of information about education and information activities among its members.
Hearing in the procedures for preparation of pharmaceutical management laws of the Autonomous Communities.
Building relationships with the media both professional and general.
Definition and dissemination of functions of the pharmacist integrated in primary health care structures.
Definition and dissemination of postgraduate specialisation program of the primary care pharmacist.
Elaboration of Informative Series: working papers with educational purposes.
Establishment of an annual educational offer specifically oriented to primary care pharmacist.
Promotion of grants intended to facilitate access to the annual educational offer.
Promotion of research through calls for awards.
Accreditation of promotional materials and training activities specifically directed at members of society.
Making the annual congress of the society.
Organization of expert groups for the analysis of pharmaceutical policy issues in the aspects clinical, economic and social.
Organization of seminars on current issues related to activities in different territories represented on the Board.
Saturday, 12 June 2010
Location and contact
Labels: Visitor information, Z15
The XV National Congress of SEFAP held in the city of Zaragoza, on October 27-29, 2010.
CONTACT
CAI VIAJES - CONTRABAJO
C/ CAPITAN PORTOLES, 12 1º
50.004 ZARAGOZA
TLF.- 976 71 81 81 / 976 21 80 89
FAX.- 976 71 84 38
congresos@caiviajes.es
Site location
WTC ZARAGOZA
Zoom in
Site location
Zoom in
CONTACT
CAI VIAJES - CONTRABAJO
C/ CAPITAN PORTOLES, 12 1º
50.004 ZARAGOZA
TLF.- 976 71 81 81 / 976 21 80 89
FAX.- 976 71 84 38
congresos@caiviajes.es
Site location
WTC ZARAGOZA
Zoom in
Site location
Zoom in
Subscribe to:
Posts
(Atom)